In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price target of $40.00. The company’s shares opened today at $42.42.
Harrison covers the Healthcare sector, focusing on stocks such as Pharvaris, Argenx Se, and BioNTech SE. According to TipRanks, Harrison has an average return of 7.0% and a 51.20% success rate on recommended stocks.
Galapagos has an analyst consensus of Hold, with a price target consensus of $42.25, representing a -0.40% downside. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $38.00 price target.
See the top stocks recommended by analysts >>
GLPG market cap is currently $2.86B and has a P/E ratio of -17.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG:
